ArticleHepatology forum2023
Protective/preventive effects of quercetin against cyclophosphamide-induced hepatic inflammation, apoptosis and fibrosis in rats.
Article in Hepatology forum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
- Flavonoids as Nutraceuticals to Treat Inflammatory Diseases: Focusing on Quercetin, Kaempferol, Luteolin, Apigenin, Epicatechin and Their Effects on Hepatic, Nervous, and Pulmonary Systems.Foods (Basel, Switzerland) · 2026Review
- Hepatoprotective effect of dipyridamole against cyclophosphamide-induced hepatotoxicity in rats.Open veterinary journal · 2026Article
- Nivolumab and bevacizumab attenuate cisplatin-induced hepatic inflammation and apoptosis in rats.Hepatology forum · 2026Article
- Elucidating the therapeutic mechanisms of quercetin in hepatic fibrosis: an integrated metabolomic and transcriptomic analysis.Frontiers in nutrition · 2026Article
- The M1/M2 Macrophage Polarization and Hepatoprotective Activity of Quercetin in Cyclophosphamide-Induced Experimental Liver Toxicity.Veterinary medicine and science · 2025Article
- Review
- The role of mitophagy in metabolic diseases and its exercise intervention.Frontiers in physiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: The purpose of this study was to investigate the hepatoprotective effects of quercetin, a potent antioxidant, against hepatotoxicity caused by cyclophosphamide (CYC) in the rat liver using histopathological parameters. Materials and Methods: Thirty female rats were divided into five groups - control, quercetin (Q), CYC, Q+CYC, and CYC+Q. At the end of the study, the liver tissues were removed and stained with routine histological hematoxylin and eosin, Periodic acid-Schiff, and Masson's trichrome. Caspase-3 (Cas-3), B-cell lymphoma protein 2-associated X (Bax), tumor necrosis factor alpha (TNF-α), and interleukin 1 beta (IL-1β) levels were investigated in immunohistochemically stained liver tissues. Results: Histopathological examination showed that CYC caused impairment and degeneration in the structure of the hepatocyte cordon, necrosis in the periportal space, sinusoidal dilatation (p=0.000), congestion and edema (p=0.000), mononuclear cell infiltration, and increased connective tissue density (p=0.000). Cas-3, Bax, TNF-α, and IL-1β immunoreactivities were significantly higher in the CYC group (for all, p=0.000). Q administration gradually reduced histopathological structural damage and Cas-3, Bax, TNF-α (p=0.000), and IL-1β (p=0.000) intensity in the rat liver. Conclusion: The administration of Q protected the liver tissue against CYC-induced damage, and successfully protected the liver against apoptosis, inflammation, and histopathological changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.